Thrombus Aspiration in Acute ST-elevation Myocardial Infarction
TASTI
1 other identifier
observational
36
1 country
1
Brief Summary
Thirty patients with acute ST-elevation myocardial infarction treated with primary PCI and aspiration of thrombus material from the infarct related coronary artery will be included. Both cellular and non cellular content of the thrombus will be examined with morphological and immunohistochemical methods and related to time from onset of symptoms to PCI, as well as to the degree of myocardial necrosis. Furthermore, mRNA expression of selected signal molecules will be performed. In addition, peripheral venous blood samples will be drawn and analyzed for signalling molecules and corresponding mRNA expression in circulating leukocytes.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Apr 2015
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 1, 2015
CompletedFirst Submitted
Initial submission to the registry
April 8, 2016
CompletedFirst Posted
Study publicly available on registry
April 21, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 9, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
January 9, 2019
CompletedOctober 8, 2020
October 1, 2020
3.8 years
April 8, 2016
October 6, 2020
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Cell composition of the intracoronary thrombus related to symptom length
24 hours
Eligibility Criteria
Patients with acute St-elevation myocardial infarction
You may qualify if:
- Both gender
- age 18-75 years
- typical symptoms of acute myocardial infarction
- ST-elevation or presumed new left bundle branch block in the ECG
- treated with aspiration of thrombus and primary PCI in the infarct related coronary artery
You may not qualify if:
- Signs of infection
- pulmonary embolism
- chronic obstructive pulmonary disease
- arrhythmias, abnormal renal and/or liver function
- autoimmune disease
- malignant disease
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Department of Cardiology, Oslo University Hospital, Ullevål
Oslo, 0407, Norway
Related Publications (3)
Nordeng J, Solheim S, Akra S, Schandiz H, Hoffmann P, Roald B, Bendz B, Arnesen H, Helseth R, Seljeflot I. Gene expression of fibrinolytic markers in coronary thrombi. Thromb J. 2022 Apr 29;20(1):23. doi: 10.1186/s12959-022-00383-1.
PMID: 35488283DERIVEDNordeng J, Schandiz H, Solheim S, Akra S, Hoffman P, Roald B, Bendz B, Arnesen H, Helseth R, Seljeflot I. TIMP-1 expression in coronary thrombi associate with myocardial injury in ST-elevation myocardial infarction patients. Coron Artery Dis. 2022 Sep 1;33(6):446-455. doi: 10.1097/MCA.0000000000001128. Epub 2022 Jan 31.
PMID: 35102064DERIVEDNordeng J, Schandiz H, Solheim S, Akra S, Hoffman P, Roald B, Bendz B, Arnesen H, Helseth R, Seljeflot I. The Inflammasome Signaling Pathway Is Actively Regulated and Related to Myocardial Damage in Coronary Thrombi from Patients with STEMI. Mediators Inflamm. 2021 May 27;2021:5525917. doi: 10.1155/2021/5525917. eCollection 2021.
PMID: 34135690DERIVED
Biospecimen
thrombus material and blood
Study Officials
- STUDY CHAIR
Ingebjørg Seljeflot, Professor
Kirkeveien 166, 0407 Oslo, Norway
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- MD, PhD
Study Record Dates
First Submitted
April 8, 2016
First Posted
April 21, 2016
Study Start
April 1, 2015
Primary Completion
January 9, 2019
Study Completion
January 9, 2019
Last Updated
October 8, 2020
Record last verified: 2020-10